Tuesday, August 22, 2017 12:43:52 PM
But Ibalizumab is a better drug than PRO 140 for this market (covers both tropisms where PRO 140 only covers one and the patient needs to take a test to show they have the CCR5 version before being able to take PRO 140) and it will reach the market well before PRO 140 does.
The label will by necessity be for salvage patients given the trial design but that market is quite small 6,000 - 7,000 patients and Ibalizumab will likely have captured most of those patients before PRO 140 gets approved.
Fred is like a football fan coming to the others team page to post crap. Your team sucks, you team has no money, on and on. Well game on, I think our team is going to win. Ibalizumab big issue is IV, no one will want to do it. What potential does Pro 140 have in combo? Well probably better than Maraviroc.
Pears is that horrible soon to be replaced (by Pro 140) Ibalizumab can do this, this I think we can beat $2.
Recent CYDY News
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
